List of top 10 heavyweight drugs launched in 2017

[China Pharmaceutical network industry trends] recently, fiercepharma released the list of top 10 listed drugs in 2017 In 2016, FDA approved 22 new drugs After a year of extremely slow approval, the pharmaceutical industry ushered in 2017 full of vision and hope Let's take a closer look at these drugs on the list and the hope they may bring to patients (the list of the top ten heavyweight drugs on the market in 2017 was published Photo source: Baidu photo) 1 Ocrevisa common name: ocrelizumab company: Roche disease: multiple sclerosis (MS) Expected sales volume in 2022: 4.1 billion US dollars Analysts predict that one of the reasons for all of ocrevus's other new drugs in 2017 is that the MS market is facing huge changes Roche's new drug is shown to be superior to placebo in reducing disability in patients with primary progressive multiple sclerosis (PPMS) PPMs is a more difficult form of multiple sclerosis, affecting about 15% of patients with multiple sclerosis This advantage made ocrevus qualified for breakthrough therapy by FDA in February last year At the same time, two late stage clinical studies have shown that ocrevus is expected to win the indications of relapsing remitting multiple sclerosis 2 Dupixent common name: dupilumab company: Sanofi and regeneron disease: atopic dermatitis expected sales in 2022: $4.1 billion analysts expect that dupilumab of Sanofi and regeneron will be sold in the form of dupixent The candidate drug has obtained a wealth of positive data in clinical trials, at the same time, there is a lack of treatment options for solid atopic dermatitis in the market Some analysts, such as Mr Geoffrey Porges of leerink partners, have predicted that the drug could be "life changing" for many patients At the same time, the two partners are also looking at a variety of other allergy related diseases, including indications for asthma As Mr Olivier brandicourt, CEO of Sanofi, said in a speech at the JPMorgan Healthcare Conference in January: "to be frank, dupixent itself is a product pipeline." 3 General name of semaglutide: semaglutide company: Novo Nordisk disease: expected sales of diabetes in 2022: US $2.2 billion Novo Nordisk hopes that its new weekly GLP-1 diabetes drug semaglutide can reach the "heavyweight" position after being put on the market At present, the relevant clinical result data seems to be expected to achieve this Novartis Nordisk's candidate product has already distanced itself from several major players in the field of diabetes At last June's annual meeting of the American Diabetes Association, Novartis Nordisk released two studies showing that the drug outperformed some products already on the market, including insulin In addition, semaglutide has been shown to reduce the overall risk of cardiovascular disease In a study called sustain6, published last September, weekly use of the drug reduced the risk of heart attack, stroke and cardiovascular death by 26% At present, only two other diabetes drugs have obtained data on cardiovascular benefits, Novartis' own Victoza, Eli Lilly and borhringer Ingelheim's SGLT2 drug jardiance Novo Nordisk plans to launch a follow-up outcome trial to increase the number of cardiovascular cases of semaglutide immediately after drug approval And it is recruiting patients for more comparative studies, with HbA1c as the primary endpoint and weight and hypoglycemia events as secondary endpoints At the same time, Novo Nordisk has developed an oral form of semaglutide, which will be one of these drugs 4 Durvalumab common name: durvalumab company: AstraZeneca disease area: cancer immunotherapy expected sales in 2022: $1.9 billion if the durvalumab of AstraZeneca is approved, there will be another immunocheckpoint inhibitor on the market AstraZeneca, like others, is targeting the non-small cell lung cancer market At the same time, the British drug maker has long been developing a combination therapy that matches durvalumab with another potential drug, tremelimumab, a CTLA-4 drug, to improve efficacy Last February, the drug was approved by the FDA as a breakthrough treatment for urothelial bladder cancer At the same time, AstraZeneca is also in the process of approving the indications for head and neck cancer 5 General name of niraparib: niraparib company: tesaro disease: cancer 2022 expected sales: 1.9 billion US dollars After lynparza of AstraZeneca and rubraca of Clovis, niraparib will be the third PARP inhibitor in the market When the new drug tesaro comes on the market, it may face a larger market target Research data show that it is not only beneficial to women with BRCA gene mutation, but also to those without BRCA gene mutation The trial results released at the European Society of Medical Oncology Conference last fall showed that compared with placebo, the drug provided a 15.5-month progression free survival advantage in patients with BRCA mutated ovarian cancer and a 5.4-month advantage in women without mutations In a subgroup of non BRCA cancers, 12.9 months were positive for niraparib delayed cancer progression test, compared with 3.8 months in the control group, with an improvement period of more than 9 months Dr Mansoor Raza Mirza of Copenhagen University said: "we have never seen such a huge benefit in the progression free survival of recurrent ovarian cancer Niraparib significantly improved all endpoints in a wide range of patient groups, up to 70% of patients with oonest cancer." Tesaro rolled it over to FDA in November and has been given FDA priority status The FDA does not plan to hold another Advisory Committee meeting to discuss the application, which analysts see as a good sign Seamus Fernandez, an analyst at leerink partners, said recently that when niraparib was approved, he had high expectations that the drug would receive a "broad label." The FDA's decision date for the drug is June 30 this year Niraparib's first possible approval will be for second-line treatment of ovarian cancer, but tesaro is also studying the drug in primary patients, hoping to eventually get first-line treatment approval Tessaro is also conducting clinical trials of niraparib in the treatment of breast cancer 6 Barictinib common name: barictinib company: Eli Lilly and Incyte disease: rheumatoid arthritis expected sales in 2022: $1.8 billion in response to the huge post cliff cycle, Lilly is striving to achieve the goal of launching 20 new drugs between 2014 and 2023 Some analysts, including EP vantage, predict that barictinib, a new oral rheumatoid arthritis drug, may be one of the major successful demonstrations, developed in collaboration with Incyte Barictinib already has plenty of positive data to show off Last year, Lilly strengthened the results of its data collection and long-term extension study, which showed that the positive impact of barictinib application could last for at least 48 weeks Recently, the company learned that the FDA's decision date for the drug was mid April 7 General name of lee011: ribociclib company: Novartis disease: expected sales of breast cancer in 2022: US $1.6 billion CDK 4 / 6 new drug lee011 of Novartis company, also known as ribociclib EP analysts believe its outlook is likely to weigh heavily in 2022 In November last year, lee011 obtained the priority review qualification issued by FDA, accelerating its regulatory application path Its phase 3 clinical research data is very good, and Mr Tim Anderson, an analyst at Bernstein, praised its treatment efficiency Looking forward to the future, the company also hopes to generate "real key" data in the premenopausal women group 8 Kte-c19 common name: axicabagene ciloleucel company: Kit Pharma disease: non Hodgkin's lymphoma The expected sales volume in 2022 is $1.4 billion Later this year, kit Pharma hopes to push its blood cancer candidate drug product kte-c19 (aka axiabagene ciloleucel) into the U.S market and become a biomedical company that has been successfully approved to be listed in car-t In early December 2016, kite submitted a rolling application for kte-c19 to the FDA At the same time, Novartis also actively launched negotiations and communication with FDA Its car-t products are aimed at recurrent or refractory aggressive B-cell non Hodgkin's lymphoma (NHL) Goldman Sachs has previously said that by 2026, kte-c19 sales are expected to reach $1.9 billion The total may depend on the ability to expand to other indications, including solid tumors 9 Ingrezza common name: valbenazine company: neurocrine disease: tardive dyskinesia expected sales in 2022: $1.3 billion may be soon, and neurocrine in San Diego will receive a decision on ingrezza from FDA, aiming at the treatment of non voluntary tardive dyskinesia After obtaining the qualification of fast track and breakthrough therapy, FDA, the US regulatory agency, accepted the company's application under the priority review system and will make a ruling before April 11 If ingrezza gets the FDA's "green light," it will become an approved drug to treat this kind of disease The obvious symptoms of patients are repetitive actions, including licking their tongue, making faces and blinking their eyes According to neurocrine, the treatment significantly improved patients' overall symptoms, and the study did not present any new safety concerns In addition, Mr Geoff Meacham, an analyst at Barclays, wrote in a note to clients that "the insights from the study should help to develop an appropriate phase 3 scenario" and noted that "we believe the results are generally positive." 10 Spinraza common name: nusinersen company: Biogen and Ionis disease: spinal muscular atrophy expected sales in 2022: US $1.3 billion at the end of last year, the drug spinraza, which was jointly developed by Biogen and Ionis, was approved by FDA earlier than expected and became the first drug in the market to treat spinal muscular atrophy Analysts expect spinraza to be a successful product for Biogen and Ionis Mr Geoffrey Porges, an analyst at leerink partners, raised the drug's 2020 sales forecast to $2 billion, and he expects 1700 patients to be treated this year "We expect spinraza's IPO outlook to exceed expectations," commented Mr Joshua schimmer, an analyst at Piper Jaffray